Literature DB >> 1751406

Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell line.

A Negroni1, S Scarpa, A Romeo, S Ferrari, A Modesti, G Raschellà.   

Abstract

The effects of an antisense oligodeoxynucleotide to codons 2-7 of the oncogene MYCN on the human neuroblastoma cell line LAN-5 were studied. Treated cells showed a decreased MYCN protein expression and synthesis by immunoperoxidase staining and immunoprecipitation. At the same time, the replication rate was inhibited, and the phenotype was modified toward a more differentiated type. Our data suggest the involvement of oncogene MYCN in both proliferative and differentiative processes.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1751406

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN： 1044-9523


  28 in total

1.  Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules.

Authors:  M V Corrias; F Guarnaccia; M Ponzoni
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  AF64A-induced changes in N-myc expression in the LA-N-2 human neuroblastoma cell line are modulated by choline and hemicholinium-3.

Authors:  L R Santiago; L C Erickson; I Hanin
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

3.  Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

Authors:  Louis Chesler; Chris Schlieve; David D Goldenberg; Anna Kenney; Grace Kim; Alex McMillan; Katherine K Matthay; David Rowitch; William A Weiss
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

4.  MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.

Authors:  Jung-Hee Kang; Piotr G Rychahou; Titilope A Ishola; Jingbo Qiao; B Mark Evers; Dai H Chung
Journal:  Biochem Biophys Res Commun       Date:  2006-10-12       Impact factor: 3.575

5.  Docosahexaenoic acid-containing phosphatidylethanolamine enhances HL-60 cell differentiation by regulation of c-jun and c-myc expression.

Authors:  Hideki Ishigamori; Masashi Hosokawa; Hiroyuki Kohno; Takuji Tanaka; Kazuo Miyashita; Koretaro Takahashi
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

6.  Modulation of N-myc expression alters the invasiveness of neuroblastoma.

Authors:  L A Goodman; B C Liu; C J Thiele; M L Schmidt; S L Cohn; J M Yamashiro; D S Pai; N Ikegaki; R K Wada
Journal:  Clin Exp Metastasis       Date:  1997-03       Impact factor: 5.150

7.  Targeting MYCN IRES in MYCN-amplified neuroblastoma with miR-375 inhibits tumor growth and sensitizes tumor cells to radiation.

Authors:  Hailong Zhang; Tao Liu; Sha Yi; Lubing Gu; Muxiang Zhou
Journal:  Mol Oncol       Date:  2015-03-24       Impact factor: 6.603

8.  Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification.

Authors:  Loen M Hansford; Wayne D Thomas; Joanna M Keating; Catherine A Burkhart; Anne E Peaston; Murray D Norris; Michelle Haber; Patricia J Armati; William A Weiss; Glenn M Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

9.  Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.

Authors:  Rhamy Zeid; Matthew A Lawlor; Evon Poon; Jaime M Reyes; Mariateresa Fulciniti; Michael A Lopez; Thomas G Scott; Behnam Nabet; Michael A Erb; Georg E Winter; Zoe Jacobson; Donald R Polaski; Kristen L Karlin; Rachel A Hirsch; Nikhil P Munshi; Thomas F Westbrook; Louis Chesler; Charles Y Lin; James E Bradner
Journal:  Nat Genet       Date:  2018-01-29       Impact factor: 38.330

10.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.